共 50 条
- [41] Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 studyCANCER RESEARCH, 2018, 78 (13)Cortes, JavierDieras, VeroniqueLorenzen, SylvieMontemurro, FilippoRiera-Knorrenschild, JorgeThuss-Patience, PeterAllegrini, GiacomoDe laurentiis, MicheleLichinitser, MikhailLohrisch, CarolinePerez-Garcia, JoseRicci, FrancescoSakaeva, DinaSerpanchy, RosanneSufliarsky, JozefVidal, MariaIrahara, NatsumiWohlfarth, ChristineAout, MounirGelmon, Karen
- [42] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Jin, JinWang, BeiGao, YuyingSamant, MeghanLi, ChunzeSong, ChunyanSwain, Sandra M.Untch, MichaelGirish, Sandhya
- [43] A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Miller, K.Gianni, L.Andre, F.Dieras, V.Mahtani, R. L.Harbeck, N.Huang, J. E.Shih, T.Choi, Y.Burris, H. A., III
- [44] HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (03): : 332 - 336Braso-Maristany, FaraGriguolo, GaiaChic, NuriaPascual, TomasPare, LaiaMaues, JuliaGalvan, PatriciaDieci, Maria VittoriaMiglietta, FedericaGiarratano, TommasoMartinez-Saez, OlgaMarin-Aguilera, MercedesSchettini, FrancescoConte, BenedettaAngelats, LauraVidal, MariaAdamo, BarbaraMunoz, MontserratSanfeliu, EstherGonzalez, BlancaVivancos, AnaVillagrasa, PatriciaParker, Joel S.Perou, Charles M.Conte, PierFrancoPrat, AleixGuarneri, Valentina
- [45] Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysisDRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3235 - 3244Zhang, JingLi, JinyingZhu, ChenjingSong, YanlinXia, FanMa, Xuelei
- [46] Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literatureECANCERMEDICALSCIENCE, 2015, 9Borges, Giuliano SantosRovere, Rodrigo KraftKappel Dias, Stephanie MereniukChong, Fernando HenriqueMorais, Mayara dos Santos
- [47] T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choiceEUROPEAN JOURNAL OF CANCER, 2013, 49 : S7 - S8Wildiers, H.Kim, S. B.Gonzalez-Martin, A.LoRusso, P. M.Ferrero, J. M.Smitt, M.Yu, R.Leung, A.Krop, I. E.
- [48] Pharmacokinetic (PK) Interaction Potential of Trastuzumab-DM1 (T-DM1) and Pertuzumab (P) in Pts with HER2-Positive, Locally Advanced or MBC: Results from a Phase 1b/2 StudyCANCER RESEARCH, 2010, 70Burris, H. A., IIILu, D.Dees, E. C.Cortes, J.Yi, J-HShih, T.Girish, S.
- [49] Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literatureCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 96 - 106Martinez, Maria TeresaPerez-Fidalgo, Jose AlejandroMartin-Martorell, PalomaCejalvo, Juan MiguelPons, VanesaBermejo, BegonaMartin, MiguelAlbanell, JoanLluch, Ana
- [50] A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancerCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 503 - 511Paridaens, R.Rixe, O.Pinel, M. C.Wildiers, H.Zorza, G.Ferre, P.Roche, H.